0001193125-22-114235.txt : 20220422 0001193125-22-114235.hdr.sgml : 20220422 20220422081101 ACCESSION NUMBER: 0001193125-22-114235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220422 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220422 DATE AS OF CHANGE: 20220422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 22843431 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d326102d8k.htm FORM 8-K Form 8-K
false 0000860730 0000860730 2022-04-22 2022-04-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 22, 2022

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

   37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, $.01 par value per share    HCA    New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On April 22, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2022, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On April 22, 2022, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2022, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On April 22, 2022, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share of the Company’s common stock. The dividend will be paid on June 30, 2022 to stockholders of record at the close of business on June 16, 2022.

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit 99.1    Press Release, dated April 22, 2022
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: April 22, 2022

EX-99.1 2 d326102dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   LOGO

 

 

 

INVESTOR CONTACT:   

FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Frank Morgan    Harlow Sumerford
615-344-2688    615-344-1851

HCA Healthcare Reports First Quarter 2022 Results

Revises 2022 Guidance

Nashville, Tenn., April 22, 2022 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2022.

Key first quarter metrics (all percentage changes compare 1Q 2022 to 1Q 2021 unless otherwise noted):

 

  •  

Revenues totaled $14.945 billion

 

  •  

Net income attributable to HCA Healthcare, Inc. totaled $1.273 billion, or $4.14 per diluted share

 

  •  

Adjusted EBITDA totaled $2.944 billion

 

  •  

Cash flows from operating activities totaled $1.345 billion

 

  •  

Same facility admissions increased 2.1 percent and same facility equivalent admissions increased 5.0 percent

“As always, our colleagues and physicians continued to show-up and deliver on our promise to provide high quality care to our patients,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “I want to thank them for their commitment and hard work as we hopefully exit the COVID-19 pandemic. In the first quarter, we had a number of positive volume and revenue indicators. Unfortunately, they were offset by higher than expected inflationary pressures on labor costs.”

Revenues in the first quarter of 2022 increased to $14.945 billion, compared to $13.977 billion in the first quarter of 2021. Net income attributable to HCA Healthcare, Inc. totaled $1.273 billion, or $4.14 per diluted share, compared to $1.423 billion, or $4.14 per diluted share, in the first quarter of 2021. Results for the first quarter of 2022 included gains on sales of facilities of $10 million, or $0.02 per diluted share. In March 2022, the state of Texas received approval from the Centers for Medicare and Medicaid Services to implement its proposed directed payment program effective for the current program year that began September 1, 2021. Revenues for the first quarter of 2022 include approximately $244 million related to this program for the period September through December 2021. Other operating expenses include approximately $90 million from provider tax assessments related to the same period in 2021.

 

1

For the first quarter of 2022, Adjusted EBITDA totaled $2.944 billion, compared to $3.052 billion in the first quarter of 2021. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions increased 2.1 percent and same facility equivalent admissions increased 5.0 percent in the first quarter of 2022, compared to the prior year period. Same facility emergency room visits increased 14.6 percent in the first quarter of 2022, compared to the prior year period. Same facility inpatient surgeries increased 0.8 percent while same facility outpatient surgeries increased 6.8 percent in the first quarter of 2022 compared to the same period of 2021. Same facility revenue per equivalent admission increased 2.7 percent in the first quarter of 2022, compared to the first quarter of 2021.

Balance Sheet and Cash Flows from Operations

As of March 31, 2022, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $2.371 billion, total debt of $37.696 billion, and total assets of $52.208 billion. During the first quarter of 2022, capital expenditures totaled $861 million, excluding acquisitions. Cash flows provided by operating activities in the first quarter totaled $1.345 billion, compared to $1.988 billion in the first quarter of 2021.

During the first quarter of 2022, the Company repurchased 8.375 million shares of its common stock at a cost of $2.101 billion. The Company had $6.485 billion remaining under its repurchase authorization as of March 31, 2022. As of March 31, 2022, the Company had $6.435 billion of availability under its credit facilities.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share on the Company’s common stock. The dividend will be paid on June 30, 2022 to stockholders of record at the close of business on June 16, 2022.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

2022 Revised Guidance

The 2022 guidance ranges for the year have been revised from our fourth quarter release as follows:

 

   

Previous 2022 Guidance Range

as of January 27, 2022

  

2022 Guidance Range as
of April 22, 2022

Revenues

   $60.0 to $62.0 billion   $59.5 to $61.5 billion

Net Income Attributable to HCA Healthcare, Inc.

   $5.550 to $5.835 billion   $4.950 to $5.340 billion

Adjusted EBITDA

   $12.55 to $13.05 billion   $11.8 to $12.4 billion

EPS (diluted)

   $18.40 to $19.20 per diluted share   $16.40 to $17.60 per diluted share

 

2

The Company’s 2022 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding the impact of the COVID-19 pandemic and related government legislation, labor cost and inflation and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.

About the Company

As of March 31, 2022, HCA operated 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2022, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to COVID-19, including, without limitation, the length and severity of the pandemic and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume of COVID-19 patients cared for across our health systems; measures we are taking to respond to the COVID-19 pandemic; the impact and terms of government and administrative regulation and stimulus and relief measures (including the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 (“ARPA”) and other enacted and potential future legislation) and whether various stimulus and relief programs continue or new similar programs are enacted in the future; changes in revenues due to declining patient

 

3

volumes, changes in payer mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions, including the impact of any current or future vaccine mandates; supply shortages and disruptions; and the timing, availability and adoption of effective medical treatments and vaccines (including boosters), (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including but not limited to, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), and the effects of additional changes to the Affordable Care Act, its implementation, or interpretation (including through executive orders and court challenges), and proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), and also including any such laws or governmental regulations which are adopted in response to the COVID-19 pandemic, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 (“PAYGO Act”) as a result of the federal budget deficit impact of the ARPA, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry) resulting from the COVID-19 pandemic, (16) the emergence of and effects related to other pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and

 

4

litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (25) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

5

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

First Quarter

Unaudited

(Dollars in millions, except per share amounts)

 

     2022     2021  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 14,945       100.0 %    $ 13,977       100.0 % 

Salaries and benefits

      6,939       46.4       6,301       45.1  

Supplies

      2,321       15.5       2,224       15.9  

Other operating expenses

      2,752       18.5       2,421       17.4  

Equity in earnings of affiliates

      (11 )      (0.1 )      (21 )      (0.2 ) 

Depreciation and amortization

      732       5.0       697       5.0  

Interest expense

      408       2.7       384       2.7  

Gains on sales of facilities

      (10 )      (0.1 )      (2 )      —  
  

 

 

    

 

 

    

 

 

    

 

 

  
     13,131       87.9       12,004       85.9  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      1,814       12.1       1,973       14.1  

Provision for income taxes

      349       2.3       393       2.8  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      1,465       9.8       1,580       11.3  

Net income attributable to noncontrolling interests

      192       1.3       157       1.1  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

    $ 1,273       8.5     $ 1,423       10.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 4.14       $ 4.14    

Shares used in computing diluted earnings per share (millions)

      307.374         343.321    

Comprehensive income attributable to HCA Healthcare, Inc.

    $ 1,230       $ 1,434    
  

 

 

      

 

 

    

 

6

HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

Unaudited

(Dollars in millions)

 

     March 31,     December 31,  
     2022     2021  

ASSETS

     

Current assets:

     

Cash and cash equivalents

    $ 2,371     $ 1,451  

Accounts receivable

      8,520       8,095  

Inventories

      2,003       1,986  

Other

      2,112       2,010  
  

 

 

    

 

 

  
     15,006       13,542  

Property and equipment, at cost

      52,042       51,350  

Accumulated depreciation

      (27,814 )      (27,287 ) 
  

 

 

    

 

 

  
     24,228       24,063  

Investments of insurance subsidiaries

      408       438  

Investments in and advances to affiliates

      441       448  

Goodwill and other intangible assets

      9,525       9,540  

Right-of-use operating lease assets

      2,138       2,113  

Other

      462       598  
  

 

 

    

 

 

  
   $ 52,208     $ 50,742  
  

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

Current liabilities:

     

Accounts payable

    $ 4,010     $ 4,111  

Accrued salaries

      1,865       1,912  

Other accrued expenses

      3,157       3,322  

Long-term debt due within one year

      1,486       237  
  

 

 

    

 

 

  
     10,518       9,582  

Long-term debt, less debt issuance costs and discounts of $323 and $248

      36,210       34,342  

Professional liability risks

      1,508       1,514  

Right-of-use operating lease obligations

      1,790       1,755  

Income taxes and other liabilities

      1,768       2,060  

Stockholders’ equity:

     

Stockholders’ deficit attributable to HCA Healthcare, Inc.

      (2,033 )      (933 ) 

Noncontrolling interests

      2,447       2,422  
  

 

 

    

 

 

  
     414       1,489  
  

 

 

    

 

 

  
   $ 52,208     $ 50,742  
  

 

 

    

 

 

  

 

7

HCA Healthcare, Inc.

Condensed Consolidated Statements of Cash Flows

First Quarter

Unaudited

(Dollars in millions)

 

     2022     2021  

Cash flows from operating activities:

     

Net income

    $ 1,465     $ 1,580  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Decrease in cash from operating assets and liabilities:

     

Accounts receivable

      (427 )      (371 ) 

Inventories and other assets

      (121 )      (85 ) 

Accounts payable and accrued expenses

      (771 )      (371 ) 

Depreciation and amortization

      732       697  

Income taxes

      346       406  

Gains on sales of facilities

      (10 )      (2 ) 

Amortization of debt issuance costs and discounts

      7       8  

Share-based compensation

      86       97  

Other

      38       29  
  

 

 

    

 

 

  

Net cash provided by operating activities

      1,345       1,988  
  

 

 

    

 

 

  

Cash flows from investing activities:

     

Purchase of property and equipment

      (861 )      (654 ) 

Acquisition of hospitals and health care entities

      (2 )      (22 ) 

Sales of hospitals and health care entities

      14       20  

Change in investments

      10       (2 ) 

Other

      (6 )      9  
  

 

 

    

 

 

  

Net cash used in investing activities

      (845 )      (649 ) 
  

 

 

    

 

 

  

Cash flows from financing activities:

     

Issuances of long-term debt

      5,966       —  

Net change in revolving credit facilities

      (2,780 )      80  

Repayment of long-term debt

      (66 )      (47 ) 

Distributions to noncontrolling interests

      (171 )      (234 ) 

Payment of debt issuance costs

      (49 )      —  

Payment of dividends

      (177 )      (169 ) 

Repurchase of common stock

      (2,101 )      (1,527 ) 

Other

      (197 )      (207 ) 
  

 

 

    

 

 

  

Net cash provided by (used in) financing activities

      425       (2,104 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash and cash equivalents

      (5 )      2  
  

 

 

    

 

 

  

Change in cash and cash equivalents

      920       (763 ) 

Cash and cash equivalents at beginning of period

      1,451       1,793  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 2,371     $ 1,030  
  

 

 

    

 

 

  

Interest payments

    $ 408     $ 375  

Income tax payments (refunds), net

    $ 3     $ (13 ) 

 

8

HCA Healthcare, Inc.

Operating Statistics

 

     First Quarter  
     2022     2021  

Operations:

     

Number of Hospitals

      182       186  

Number of Freestanding Outpatient Surgery Centers*

      124       121  

Licensed Beds at End of Period

      48,892       49,561  

Weighted Average Beds in Service

      41,818       42,363  

Reported:

     

Admissions

      506,956       506,380  

% Change

      0.1 %   

Equivalent Admissions

      859,290       832,489  

% Change

      3.2 %   

Revenue per Equivalent Admission

    $ 17,392     $ 16,789  

% Change

      3.6 %   

Inpatient Revenue per Admission

    $ 17,694     $ 17,090  

% Change

      3.5 %   

Patient Days

      2,681,718       2,671,041  

% Change

      0.4 %   

Equivalent Patient Days

      4,545,512       4,391,191  

% Change

      3.5 %   

Inpatient Surgery Cases

      126,880       127,590  

% Change

      -0.6 %   

Outpatient Surgery Cases

      247,421       231,228  

% Change

      7.0 %   

Emergency Room Visits

      2,056,389       1,841,778  

% Change

      11.7 %   

Outpatient Revenues as a Percentage of Patient Revenues

      37.4 %      35.8 % 

Average Length of Stay (days)

      5.290       5.275  

Occupancy (weighted average beds in service)

      71.3 %      70.1 % 

Same Facility:

     

Admissions

      503,068       492,940  

% Change

      2.1 %   

Equivalent Admissions

      849,682       808,915  

% Change

      5.0 %   

Revenue per Equivalent Admission

    $ 17,367     $ 16,916  

% Change

      2.7 %   

Inpatient Revenue per Admission

    $ 17,727     $ 17,172  

% Change

      3.2 %   

Inpatient Surgery Cases

      125,995       125,024  

% Change

      0.8 %   

Outpatient Surgery Cases

      240,718       225,439  

% Change

      6.8 %   

Emergency Room Visits

      2,034,692       1,775,884  

% Change

      14.6 %   

 

*

Excludes freestanding endoscopy centers (21 centers at both March 31, 2022 and March 31, 2021).

 

9

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

     First Quarter  
     2022     2021  

Revenues

    $ 14,945     $ 13,977  

Net income attributable to HCA Healthcare, Inc.

    $ 1,273     $ 1,423  

Gains on sales of facilities (net of tax)

      (8 )      (1 ) 
  

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities (a)

      1,265       1,422  

Depreciation and amortization

      732       697  

Interest expense

      408       384  

Provision for income taxes

      347       392  

Net income attributable to noncontrolling interests

      192       157  
  

 

 

    

 

 

  

Adjusted EBITDA (a)

    $ 2,944     $ 3,052  
  

 

 

    

 

 

  

Adjusted EBITDA margin (a)

      19.7 %      21.8 % 

Diluted earnings per share:

     

Net income attributable to HCA Healthcare, Inc.

    $ 4.14     $ 4.14  

Gains on sales of facilities

      (0.02 )      —  
  

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities (a)

    $ 4.12     $ 4.14  
  

 

 

    

 

 

  

Shares used in computing diluted earnings per share (millions)

      307.374       343.321  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that gains on sales of facilities will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

10

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2022 Operating Results Forecast

(Dollars in millions, except per share amounts)

 

     For the Year Ending  
     December 31, 2022  
     Low      High  

Revenues

    $ 59,500      $ 61,500  

Net income attributable to HCA Healthcare, Inc. (a)

    $ 4,950      $ 5,340  

Depreciation and amortization

      2,980        3,020  

Interest expense

      1,690        1,710  

Provision for income taxes

      1,470        1,580  

Net income attributable to noncontrolling interests

      710        750  
  

 

 

     

 

 

  

Adjusted EBITDA (a) (b)

    $ 11,800      $ 12,400  
  

 

 

     

 

 

  

Diluted earnings per share:

      

Net income attributable to HCA Healthcare, Inc.

    $ 16.40      $ 17.60  

Shares used in computing diluted earnings per share (millions)

      303.000        303.000  

The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

11

EX-101.SCH 3 hca-20220422.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20220422_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20220422_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g326102g1.jpg GRAPHIC begin 644 g326102g1.jpg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g326102g2.jpg GRAPHIC begin 644 g326102g2.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 22, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Apr. 22, 2022
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 d326102d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2022-04-22 2022-04-22 false 0000860730 8-K 2022-04-22 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d326102d8k.htm d326102dex991.htm hca-20220422.xsd hca-20220422_lab.xml hca-20220422_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d326102d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d326102d8k.htm" ] }, "labelLink": { "local": [ "hca-20220422_lab.xml" ] }, "presentationLink": { "local": [ "hca-20220422_pre.xml" ] }, "schema": { "local": [ "hca-20220422.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20220422", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d326102d8k.htm", "contextRef": "duration_2022-04-22_to_2022-04-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d326102d8k.htm", "contextRef": "duration_2022-04-22_to_2022-04-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.hcahealthcare.com//20220422/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-114235-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-114235-xbrl.zip M4$L#!!0 ( &!!EE0R'3RI)P\ --> . 9#,R-C$P,F0X:RYH=&WM M7.ESXD86_YZJ_ ]=3)+"508D@0_PD?)@/,-FQK@PL\GNEZE&:DSO"$GIE@SD MK]_WNB40]V&P/8E=-8.DOE__WMW2^:^#GDL>F9#<]RXR9M[($.;9OL.]AXM, M%'9RIQGRZ^6//YQW0Z@(E3U9<1B_R'3#,*@4"H.V$7\'RMM_#55A&R;)&S*DGCT:)PK% MPEF5"U":5.32+UGFR9(EQ#5�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end